Effects of Treatment of High-Grade Serous Ovarian Cancer Tumors at the Single-Cell Level
High-grade serous ovarian cancer (HGSOC) is a major health concern for women due to its subtle onset, aggressive progression, high recurrence rate, and resistance to standard therapies. Olaparib, a PARP inhibitor, is currently used as maintenance therapy following removal of tumors. C26A6 is a promising therapeutic which has been shown to inhibit breast cancer progression in mouse models by disrup
